Sustained disease remission after spontaneous HBeAg seroconversion is associated with reduction in fibrosis progression in chronic hepatitis B Chinese patients

被引:77
作者
Hui, Chee-Kin
Leung, Nancy
Shek, Tony W. H.
Yao, Hung
Lee, Wai-Ki
Lai, Jak-Yiu
Lai, Sik-To
Wong, Wai-Man
Lai, Lawrence S. W.
Poon, Ronnie T. P.
Lo, Chung-Mau
Fan, Sheung-Tat
Lau, George K. K.
机构
[1] Univ Hong Kong, Dept Med, Queen Mary Hosp, Hong Kong, Hong Kong, Peoples R China
[2] Univ Hong Kong, Queen Mary Hosp, Res Ctr Infect & Immun, Hong Kong, Hong Kong, Peoples R China
[3] Univ Hong Kong, Queen Mary Hosp, Dept Surg, Hong Kong, Hong Kong, Peoples R China
[4] Alice Ho Miu Ling Nethersole Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China
[5] Queen Mary Hosp, Dept Pathol, Hong Kong, Hong Kong, Peoples R China
[6] Princess Margaret Hosp, Dept Pathol, Hong Kong, Hong Kong, Peoples R China
[7] Tuen Mun Hosp, Dept Pathol, Hong Kong, Hong Kong, Peoples R China
[8] Princess Margaret Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China
[9] St Pauls Hosp, Hong Kong, Hong Kong, Peoples R China
[10] Caritas Med Ctr, Dept Med, Hong Kong, Hong Kong, Peoples R China
关键词
D O I
10.1002/hep.21758
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Recently, controversies have arisen about whether hepatitis B e antigen (HBeAg) seroconversion can result in regression of fibrosis, thus improving the clinical outcome of Chinese patients with chronic hepatitis B. In this study, we determined if spontaneous HBeAg seroconversion is associated with regression of fibrosis in Chinese chronic hepatitis B patients. We evaluated the histology of liver samples from 128 HBeAg-positive treatment-naive Chinese patients who had undergone 2 liver biopsies over the years. Regression of fibrosis was defined as a decrease in fibrosis stage of at least 1 point. Sustained disease remission was defined as HBeAg seroconversion and hepatitis B virus (HBV) DNA < 10(4) copies/ml at follow-up liver biopsy. The mean duration (+/- standard error of the mean) between the initial and follow-up liver biopsies was 43.9 +/- 3.4 months. Regression of fibrosis was higher in patients with sustained disease remission (5 of 13 [38.5%] versus 22 of 115 [19.1%], P < 0.00005), patients who were younger (20-29 years old) at initial liver biopsy (17 of 54 [31.5%] versus 10 of 74 [13.5%], P = 0.0004), and patients with genotype B (17 of 43 [39.5%] versus 10 of 85 [11.8%], P = 0.004). On multivariate analysis, sustained disease remission (relative risk [RR] 3.00, 95% confidence interval [95% CI] 1.29-7.01, P = 0.01) and being 20-29 years old at initial liver biopsy (RR 2.94, 95% CI 1.01-8.62, P = 0.04) were independently associated with regression of fibrosis. The rate of fibrosis progression was lower in patients with sustained disease remission than in those who remained HBeAg positive (median 0 fibrosis units/year, range -2.00 to -0.70 fibrosis units/year, versus median 0.51 fibrosis units/year, range 0 to +2.03 fibrosis units/year, P = 0.02). Conclusion: Spontaneous sustained remission of disease is associated not only with little progression of fibrosis but also with regression of fibrosis.
引用
收藏
页码:690 / 698
页数:9
相关论文
共 47 条
  • [41] Liver transplantation and hepatitis B
    Poterucha, JJ
    Wiesner, RH
    [J]. ANNALS OF INTERNAL MEDICINE, 1997, 126 (10) : 805 - 807
  • [42] A comparison of fibrosis progression in chronic liver diseases
    Poynard, T
    Mathurin, P
    Lai, CL
    Guyader, D
    Poupon, R
    Tainturier, MH
    Myers, RP
    Muntenau, M
    Ratziu, V
    Manns, M
    Vogel, A
    Capron, F
    Chedid, A
    Bedossa, P
    [J]. JOURNAL OF HEPATOLOGY, 2003, 38 (03) : 257 - 265
  • [43] An appraisal of the histopathological assessment of liver fibrosis
    Standish, RA
    Cholongitas, E
    Dhillon, A
    Burroughs, AK
    Dhillon, AP
    [J]. GUT, 2006, 55 (04) : 569 - 578
  • [44] Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B:: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase
    van Nunen, AB
    Hansen, BE
    Suh, DJ
    Löhr, DJS
    Chemello, L
    Fontaine, H
    Heathcote, J
    Song, BC
    Janssen, HLA
    de Man, RA
    Schalm, SW
    [J]. GUT, 2003, 52 (03) : 420 - 424
  • [45] WALDSTEIN SS, 1950, ARCH PATHOL, V50, P326
  • [46] Hepatitis B e antigen and the risk of hepatocellular carcinoma
    Yang, HI
    Lu, SN
    Liaw, YF
    You, SL
    Sun, CA
    Wang, UY
    Hsiao, CK
    Chen, PJ
    Chen, DS
    Chen, CJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (03) : 168 - 174
  • [47] HEPATITIS B FDN WHAT